216 related articles for article (PubMed ID: 37586066)
21. Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.
Magnusson P; Gadler F; Liv P; Mörner S
Pacing Clin Electrophysiol; 2016 Mar; 39(3):291-301. PubMed ID: 26681505
[TBL] [Abstract][Full Text] [Related]
22. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
[TBL] [Abstract][Full Text] [Related]
23. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
24. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
25. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
[TBL] [Abstract][Full Text] [Related]
26. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial.
Zhang S; Ching CK; Huang D; Liu YB; Rodriguez-Guerrero DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Lexcen DR; Muckala K; Brown ML; Cheng A; Singh B;
Heart Rhythm; 2020 Mar; 17(3):468-475. PubMed ID: 31561030
[TBL] [Abstract][Full Text] [Related]
27. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
[TBL] [Abstract][Full Text] [Related]
28. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D
J Am Coll Cardiol; 2018 Oct; 72(14):1653-1676. PubMed ID: 29097297
[TBL] [Abstract][Full Text] [Related]
29. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
30. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
31. Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry.
Frommeyer G; Reinke F; Andresen D; Kleemann T; Spitzer SG; Jehle J; Brachmann J; Stellbrink C; Hochadel M; Senges J; Eckardt L
Clin Res Cardiol; 2020 Apr; 109(4):508-512. PubMed ID: 31367999
[TBL] [Abstract][Full Text] [Related]
32. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
33. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.
Maron BJ; Rowin EJ; Maron MS
Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516
[TBL] [Abstract][Full Text] [Related]
34. Risk of ventricular arrhythmias following implantable cardioverter-defibrillator generator change in patients with recovered ejection fraction: Implications for shared decision-making.
Chang DD; Pantlin PG; Benn FA; Ryan Gullatt T; Bernard ML; Elise Hiltbold A; Khatib S; Polin GM; Rogers PA; Velasco-Gonzalez C; Morin DP
J Cardiovasc Electrophysiol; 2023 Jun; 34(6):1405-1414. PubMed ID: 37146210
[TBL] [Abstract][Full Text] [Related]
35. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
36. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
[TBL] [Abstract][Full Text] [Related]
37. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.
Wang W; Lian Z; Rowin EJ; Maron BJ; Maron MS; Link MS
Circ Arrhythm Electrophysiol; 2017 Mar; 10(3):. PubMed ID: 28314849
[TBL] [Abstract][Full Text] [Related]
39. Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death.
Medeiros Pde T; Martinelli Filho M; Arteaga E; Costa R; Siqueira S; Mady C; Piegas LS; Ramires JA
Arq Bras Cardiol; 2006 Nov; 87(5):649-57. PubMed ID: 17221043
[TBL] [Abstract][Full Text] [Related]
40. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
